Karen L. Leach

Mechanism of action of the phorbol ester tumor promoters: Specific receptors for lipophilic ligands

Cells and tissue preparations specifically bind the phorbol ester tumor promoters. The agreement in structure-activity relationships between binding and biological response strongly argues that these binding sites function as phorbol ester receptors. Upon subcellular fractionation, the phorbol ester binding activity is particulate. In addition, a phorbol ester apo-receptor can be detected in cytosol which requires phospholipids for reconstitution. This apo-receptor appears to correspond to protein kinase C. Diacylglycerols, the probable natural activators of protein kinase C, competitively inhibit phorbol ester binding, consistent with their being the postulated endogenous phorbol ester analogs. In certain systems, heterogeneity of phorbol ester binding is found. An outstanding issue therefore is whether protein kinase C is the phorbol ester receptor or whether it is only the most abundant class of receptor. Although this question remains unresolved, we can demonstrate heterogeneity of phorbol ester binding by reconstitution of apo-receptor into a heterogeneous lipid environment.

Linezolid, the first oxazolidinone antibacterial agent.

Linezolid (Zyvox™) is the first member of an entirely new class of antibiotics to reach the market in over 35 years; it was approved for use in 2000. A member of the oxazolidinone class of antibiotics, linezolid is highly effective for the treatment of serious Gram‐positive infections and has activity that compares favorably with vancomycin for most clinically relevant pathogens. Zyvox is approved for use against serious Gram‐positive infections, including those caused by Streptococcus pneumoniae, and the very challenging methicillin‐resistant Staphylococcus aureus and vancomycin‐resistant Enterococcus faecium organisms. Zyvox inhibits bacterial protein synthesis by binding to 23S rRNA in the catalytic site of the 50S ribosome. It can be administered both orally and intravenously and has good tissue distribution. Recent results have demonstrated that oxazolidinone analogs related to linezolid are effective in treating pulmonary tuberculosis caused by resistant Mycobacterium tuberculosis in animal infection models and suggest additional new therapeutic applications for these antibiotics.

Potent Inhibitors of LpxC for the Treatment of Gram-Negative Infections

In this paper, we present the synthesis and SAR as well as selectivity, pharmacokinetic, and infection model data for representative analogues of a novel series of potent antibacterial LpxC inhibitors represented by hydroxamic acid.

Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections

The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.

PHORBOL ESTER RECEPTORS AND THE IN VITRO EFFECTS OF TUMOR PROMOTERS

The evidence for the multistage nature of tumor promotion in vivo and for multiple subclasses of phorbol ester receptors in vitro argues that multiple mechanisms of tumor promotion exist. The existence of multiple mechanisms suggests that brute force assay for tumor promoters in vivo may be inadequate and that understanding of mechanisms may be essential. The interest in the phorbol esters is not primarily that they are environmental hazards for man, but rather that they provide a probe for phorbol ester receptors. These receptors are found in people, and modulation of their activity may play a role in tumor promotion in man.

Discovery of Dap-3 Polymyxin Analogues for the Treatment of Multidrug-Resistant Gram-Negative Nosocomial Infections

We report novel polymyxin analogues with improved antibacterial in vitro potency against polymyxin resistant recent clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa . In addition, a human renal cell in vitro assay (hRPTEC) was used to inform structure-toxicity relationships and further differentiate analogues. Replacement of the Dab-3 residue with a Dap-3 in combination with a relatively polar 6-oxo-1-phenyl-1,6-dihydropyridine-3-carbonyl side chain as a fatty acyl replacement yielded analogue 5x, which demonstrated an improved in vitro antimicrobial and renal cytotoxicity profiles relative to polymyxin B (PMB). However, in vivo PK/PD comparison of 5x and PMB in a murine neutropenic thigh model against P. aeruginosa strains with matched MICs showed that 5x was inferior to PMB in vivo, suggesting a lack of improved therapeutic index in spite of apparent in vitro advantages.

Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay

Cyclic GMP-AMP synthase (cGAS) initiates the innate immune system in response to cytosolic dsDNA. After binding and activation from dsDNA, cGAS uses ATP and GTP to synthesize 2′, 3′ -cGAMP (cGAMP), a cyclic dinucleotide second messenger with mixed 2′-5′ and 3′-5′ phosphodiester bonds. Inappropriate stimulation of cGAS has been implicated in autoimmune disease such as systemic lupus erythematosus, thus inhibition of cGAS may be of therapeutic benefit in some diseases; however, the size and polarity of the cGAS active site makes it a challenging target for the development of conventional substrate-competitive inhibitors. We report here the development of a high affinity (KD = 200 nM) inhibitor from a low affinity fragment hit with supporting biochemical and structural data showing these molecules bind to the cGAS active site. We also report a new high throughput cGAS fluorescence polarization (FP)-based assay to enable the rapid identification and optimization of cGAS inhibitors. This FP assay uses Cy5-labelled cGAMP in combination with a novel high affinity monoclonal antibody that specifically recognizes cGAMP with no cross reactivity to cAMP, cGMP, ATP, or GTP. Given its role in the innate immune response, cGAS is a promising therapeutic target for autoinflammatory disease. Our results demonstrate its druggability, provide a high affinity tool compound, and establish a high throughput assay for the identification of next generation cGAS inhibitors.

High throughput glutathione and Nrf2 assays to assess chemical and biological reactivity of cysteine-reactive compounds

Compounds that inhibit their target through covalent binding offer a number of unique advantages as potential therapeutic agents. They can achieve high ligand efficiency, and thus high potency, which can translate into a reduced drug dosage. In addition, covalent binding can result in a long duration of action of the compound and thus less frequent drug dosing. Despite these advantages, there are several safety concerns about this class of compounds because of their inherent reactivity and potential for non-specific binding to cellular proteins. The primary aim of this study was to establish the thiol reactivity of acrylamides and other cysteine-reactive groups by measuring reactivity against various cysteine-containing cellular components. Compounds were incubated with glutathione, bovine serum albumen (BSA) or human liver microsomes (HLM), and the reduction in thiol levels was quantitated using Ellmans reagent. In addition, the ability of compounds to induce Nrf2 activity in a reporter gene assay was used as a functional readout of compound reactivity. The assays were validated using known thiol-reactive compounds and Nrf2 inducers such as sulforaphane (SFP) and 1,2-dithiole-3-thione (D3T). Our results demonstrate that acrylamides possess low reactivity unless activated by electron-withdrawing N-substituents. Analogous propynamides and vinyl sulphones were more reactive than acrylamides with respect to glutathione activity but were less reactive in the Nrf2 assay. Large drug-like molecules, including irreversible kinase inhibitors targeting BTK and EGFR, were far less reactive than their lower molecular weight counterparts, suggesting that the presence of an electrophile is not sufficient to predict thiol reactivity. These studies demonstrate the utility of multiple thiol sources in addition to glutathione when assessing the thiol reactivity of covalent inhibitors.

Chapter 25. Isozymes of Protein Kinase C

Publisher Summary This chapter discusses the structure of the protein kinase C (PKC) isozymes, the biochemical properties of the coded proteins, and the use and importance of PKC type-specific reagents for exploring PKC type-specific stimulus-response coupling. A variety of hormones, growth factors, and neurotransmitters stimulate the phospholipase C-mediated hydrolysis of phosphatidylinositol biphosphate (PIP2) in tissues to produce two second messenger molecules, diacylglycerol (DAG) and inositol trisphosphate (IP 3 ). Activation of PKC is associated with increased growth, enhancement of terminal differentiation, increased exocytosis, and tumor promotion. PKC has been identified as the major cellular phorbol ester receptor, and therefore phorbol esters are often used as specific tools to explore PKC function in cells. Furthermore, because phorbol esters, particularly phorbol dibutyrate (PDBu), are less lipophilic than DAGs, they are much more suitable ligands for binding assays. Recent researches have isolated mammalian PKC complementary DNA (cDNA) clones from brain cDNA libraries. These gene cloning studies demonstrated that PKC is actually a family of genes. Currently, at least six separate genes have been separated. For all the isolated mammalian, cDNA clones code off proteins of approximately 77 kDa. Amino acid sequence conservation is greater han 90% among the bovine, rat and human α PKCs. The genes for α, β, and γ map to human chromosomes 16, 17, and 19, respectively, suggest that different control mechanisms may be involved in the expression of each of the genes.

Second stage tumor promoters: Differences in biological potency and phorbol ester receptor affinity in C6 cells

We have shown that the second stage tumor promoters mezerein (MEZ) and phorbol 12-retinoate 13-acetate (PRA) inhibit the gluccocorticoid-induced increase in glycerol phosphate dehydrogenase (GPDH) activity in C6 rat glioma cells with ED 50-values of 3.9 and 2.9 nM, respectively. Phorbol 12-myristate 13-acetate (PMA) was 10-fold less potent. MEZ was likewise more potent than PMA for inhibition of cAMP formation in response to isoproterenol. Binding competition studies using [3H]phorbol 12,13-dibutyrate ([3H]PDBu) yielded apparent Ki-values for MEZ and PRA of 50-70 nM. The large difference between the biological potencies of MEZ and PRA and their affinity for the major phorbol ester receptor suggest they may be acting through a more complicated mechanism in these cells.